NCT05275478 2026-04-15
Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors
Tango Therapeutics, Inc.
Phase 1/2 Terminated
Clinical Trials
3 trialsNCT05732831 2026-04-06
Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
Tango Therapeutics, Inc.
Phase 1/2 Recruiting
NCT06603987 2025-11-19
Using CICS-1 and SPM-011 and ï¼»18Fï¼½FBPA Commissioned by CICS and Sumitomo Heavy Industries and STELLA PHARMA
Stella Pharma Corporation
Phase 1/2 Enrolling by invitation